AssetMark Inc’s Eterna Therapeutics ERNA Stock Holding History

AssetMark Inc’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33	Hold	5	–	–	﹤0.01%	3520
2026 Q1	$26	Hold	5	–	–	﹤0.01%	3419
2025 Q4	$160	Hold	5	–	–	﹤0.01%	3275
2025 Q3	$146	Hold	5	–	–	﹤0.01%	3097
2025 Q2	$245	Hold	5	–	–	﹤0.01%	2855
2025 Q1	$356	Buy	+5	New	+$617	﹤0.01%	2466

Other funds holding ERNA

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

AssetMark Inc's ERNA Position: Q2 2026 in Review

AssetMark Inc held its Eterna Therapeutics (ERNA) position steady in Q2 2026 at 5 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #3520.

AssetMark Inc first reported a position in ERNA in Q1 2025 and has held it in 6 quarters since. The position peaked at $356 in Q1 2025. 8 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

AssetMark Inc held 5 shares of Eterna Therapeutics worth $33 as of Q2 2026.
AssetMark Inc left its Eterna Therapeutics share count unchanged in Q2 2026.
Eterna Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3520 holding.
AssetMark Inc first reported a position in Eterna Therapeutics in Q1 2025 and has held it in 6 quarters since.
AssetMark Inc's Eterna Therapeutics position peaked at $356 in Q1 2025.
8 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.